Company intelligence / Profile preview

EverEx

Ownership: Private
Development stage: Commercial

Overview

EverEx has developed an AI-powered digital therapeutics suite for musculoskeletal rehabilitation. Its flagship product, MORA Vu, received regulatory approval as a software medical device in Korea and enables remote assessment and monitoring of patients using portable devices. The company’s solutions are used by both clinicians and patients to personalize rehab plans and track progress. Clinical results are not detailed but the products have been positively received by users.

Therapeutic areas: Rheumatology
Modalities: Digital therapeutic software (AI-driven rehabilitation platform)
Industry: Digital Health Medical Devices

Drug pipeline

4 assets

MORA Cure

Clinical Trial

Indications: Patellofemoral pain syndrome

3 more assets in the full pipeline.

Request access →

Partnerships

Not specified; no major pharma/biotech partnerships disclosed as of June 2025.

Beyond the preview

Go deeper on EverEx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EverEx.

Explore the full profile